Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics (SRPT)
NASDAQ:SRPT
SRPT Stock Chart & Stats
$17.64
$1.44(1.16%)
At close: 4:00 PM EST
$17.64
$1.44(1.16%)
Day’s Range― - ―
52-Week Range$10.42 - $138.81
Previous CloseN/A
Volume185.86K
Average Volume (3M)6.36M
Market Cap
$1.82B
Enterprise Value$2.33B
Total Cash (Recent Filing)$850.99M
Total Debt (Recent Filing)$1.26B
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Mar 03, 2026EPS Estimate
-1.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.80
Shares Outstanding97,713,440
10 Day Avg. Volume7,795,195
30 Day Avg. Volume6,355,430
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)7.57
Price to Sales (P/S)6.08
P/FCF Ratio-33.73
Enterprise Value/Market Cap1.28
Enterprise Value/Revenue0.97
Enterprise Value/Gross Profit1.27
Enterprise Value/Ebitda-11.98
Forecast
1Y Price Target
$21.50Price Target Upside21.88% Upside
Rating ConsensusHold
Number of Analyst Covering23
EPS Forecast (FY)-4.26
Revenue Forecast (FY)$2.04B
Bulls Say, Bears Say
Bulls Say
Market ConfidenceThe physician survey indicates that a majority of physicians continue to prescribe Elevidys, even after patient deaths, suggesting strong market confidence.
Product UptakeSRPT's current valuation renders its risk/reward skewed to the upside given that Elevidys uptake is ramping up and sales could beat expectations.
Revenue PerformanceElevidys revenue of $132M beat consensus expectations of $95M.
Bears Say
Clinical Trial ResultsAmondys/Vyondys missed statistical significance in their confirmatory trial.
Financial PerformanceSRPT reported a Q3 net loss of $180M.
Regulatory ChallengesManagement continues to argue that real-world data and long-term use rates demonstrate benefit, but recent FDA feedback in other gene therapy programs illustrates the agency’s increasingly cautious stance toward single-arm and externally controlled datasets.
Sarepta Therapeutics News
SRPT FAQ
What was Sarepta Therapeutics’s price range in the past 12 months?
Sarepta Therapeutics lowest stock price was $10.41 and its highest was $138.81 in the past 12 months.
What is Sarepta Therapeutics’s market cap?
Sarepta Therapeutics’s market cap is $1.82B.
When is Sarepta Therapeutics’s upcoming earnings report date?
Sarepta Therapeutics’s upcoming earnings report date is Mar 03, 2026 which is in 115 days.
How were Sarepta Therapeutics’s earnings last quarter?
Sarepta Therapeutics released its earnings results on Nov 03, 2025. The company reported -$1.8 earnings per share for the quarter, missing the consensus estimate of -$0.727 by -$1.073.
Is Sarepta Therapeutics overvalued?
According to Wall Street analysts Sarepta Therapeutics’s price is currently Undervalued.
Does Sarepta Therapeutics pay dividends?
Sarepta Therapeutics does not currently pay dividends.
What is Sarepta Therapeutics’s EPS estimate?
Sarepta Therapeutics’s EPS estimate is -1.39.
How many shares outstanding does Sarepta Therapeutics have?
Sarepta Therapeutics has 97,713,440 shares outstanding.
What happened to Sarepta Therapeutics’s price movement after its last earnings report?
Sarepta Therapeutics reported an EPS of -$1.8 in its last earnings report, missing expectations of -$0.727. Following the earnings report the stock price went down -33.742%.
Which hedge fund is a major shareholder of Sarepta Therapeutics?
Currently, no hedge funds are holding shares in SRPT
Sarepta Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$21.50 (21.88% Upside)
$21.50 (21.88% Upside)
Blogger Sentiment
Neutral
SRPT Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.9%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.21%
12-Months-Change
Fundamentals
Return on Equity
-21.37%
Trailing 12-Months
Asset Growth
-2.96%
Trailing 12-Months
Company Description
Sarepta Therapeutics
Sarepta Therapeutics (SRPT) is a biopharmaceutical company focused on developing innovative therapies for rare diseases, primarily targeting genetic disorders such as Duchenne muscular dystrophy (DMD). The company operates in the biotechnology sector and is known for its pioneering work in gene therapy and RNA-targeted medicines. Sarepta's lead product candidates include exon-skipping therapies and gene replacement therapies designed to address the underlying causes of DMD and other genetic conditions.
SRPT Company Deck
SRPT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view, with significant achievements in revenue and study completions, alongside challenges such as the ESSENCE trial missing statistical significance and disruptions from paused shipments.View all SRPT earnings summariesSRPT Stock 12 Month Forecast
Average Price Target
$21.50
▲(21.88% Upside)
Technical Analysis
BioCryst
―
Mesoblast
―
Cogent Biosciences
―
Arcutis Biotherapeutics
―
Dyne Therapeutics
―
Ownership Overview
4.68% Insiders
15.11% Mutual Funds
0.03% Other Institutional Investors
52.71% Public Companies and Individual Investors